A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

March 28, 2019

Study Completion Date

March 28, 2019

Conditions
Colorectal Cancer
Interventions
DRUG

SC-006

Intravenous

DRUG

ABBV-181

Intravenous

Trial Locations (9)

28078

Carolina BioOncology Institute /ID# 202712, Huntersville

63110

Washington University-School of Medicine /ID# 160883, St Louis

73104

Oklahoma University /ID# 202713, Oklahoma City

90095

University of California, Los Angeles /ID# 160882, Los Angeles

72703-4005

Highlands Oncology Group /ID# 201182, Fayetteville

48109-5008

University of Michigan Hospitals /ID# 167101, Ann Arbor

55905-0001

Mayo Clinic - Rochester /ID# 160884, Rochester

10065-6007

Memorial Sloan Kettering Cancer Center /ID# 160881, New York

37203-1632

Tennessee Oncology-Nashville Centennial /ID# 160880, Nashville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY